High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.840
+37.7%
--
--
-0.938
-50.66%
--
--
-0.960
+6.67%
Estimates Revision
The market is revising No Change the revenue expectations for ArriVent BioPharma, Inc. (AVBP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 23.90%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1.44%
In Past 3 Month
Stock Price
Go Up
+23.90%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast AVBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVBP is 41.00 USD with a low forecast of 31.00 USD and a high forecast of 47.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.420
Low
31.00
Averages
41.00
High
47.00
Current: 24.420
Low
31.00
Averages
41.00
High
47.00
BTIG
analyst
initiated
$45
2025-12-10
New
Reason
BTIG
analyst
Price Target
$45
2025-12-10
New
initiated
Reason
As previously reported, BTIG initiated coverage of ArriVent Biopharma with a Buy rating and $45 price target. The late-stage oncology company is developing firmonertinib, which is approved in China and has accumulated extensive real-world and clinical experience, while updated data from the global Phase 1b FURTHER study demonstrate "a best-in-class profile" in first-line PACC NSCLC with 68.2% confirmed ORR and 16.0-month PFS, the analyst tells investors. The pivotal global Phase 3 FURVENT trial is now guided to read out in early 2026 following slower-than-expected event accumulation, notes the analyst, who models combined global risk-unadjusted peak sales of greater than $1B for firmonertinib.
Truist
Buy
initiated
$43
2025-11-25
Reason
Truist
Price Target
$43
2025-11-25
initiated
Buy
Reason
Truist initiated coverage of ArriVent Biopharma with a Buy rating and $43 price target. ArriVent is advancing firmonertinib, an already China-approved and U.S. Breakthrough-designated inhibitor for hard-to-treat, mutation-driven lung cancers, with two global pivotal trials underway and topline FURVENT data expected in early 2026, the analyst tells investors in a research note. The company appears positioned for more than $1B peak sales potential and additional pipeline value not yet reflected in its share price, Truist argues.
Citi
Buy
downgrade
$33 -> $31
2025-11-11
Reason
Citi
Price Target
$33 -> $31
2025-11-11
downgrade
Buy
Reason
Citi lowered the firm's price target on ArriVent Biopharma to $31 from $33 and keeps a Buy rating on the shares.
Clear Street
Kaveri Pohlman
Buy
maintain
$32 -> $47
2025-11-10
Reason
Clear Street
Kaveri Pohlman
Price Target
$32 -> $47
2025-11-10
maintain
Buy
Reason
Clear Street analyst Kaveri Pohlman raised the firm's price target on ArriVent Biopharma to $47 from $32 and keeps a Buy rating on the shares, citing heightened conviction in the success of the first-line Phase 3 Alpacca trial for PACC-mutated NSCLC based on an analysis of historical afatinib and osimertinib outcomes for both ORR and PFS. The firm raised its view of the probability of success to 65% from 30%, the analyst noted.
Citi
Yigal Nochomovitz
Buy
downgrade
$40 -> $33
2025-08-12
Reason
Citi
Yigal Nochomovitz
Price Target
$40 -> $33
2025-08-12
downgrade
Buy
Reason
Citi analyst Yigal Nochomovitz lowered the firm's price target on ArriVent Biopharma to $33 from $40 and keeps a Buy rating on the shares following the Q2 report. The firm cites the 18% dilution from July's public offering for the target cut but continues to see shared upside into ArriVent's two near-to-medium term data readouts.
H.C. Wainwright
Buy
maintain
$40 -> $42
2025-08-12
Reason
H.C. Wainwright
Price Target
$40 -> $42
2025-08-12
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on ArriVent Biopharma to $42 from $40 and keeps a Buy rating on the shares. The top-line results from the pivotal Phase 3 FURVENT trial are expected in early 2026, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for ArriVent BioPharma Inc (AVBP.O) is -6.48, compared to its 5-year average forward P/E of -6.87. For a more detailed relative valuation and DCF analysis to assess ArriVent BioPharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-6.87
Current PE
-6.48
Overvalued PE
-5.66
Undervalued PE
-8.09
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-4.81
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-3.31
Undervalued EV/EBITDA
-6.30
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AVBP News & Events
Events Timeline
(ET)
2025-11-10
08:03:30
ArriVent Biopharma announces Q3 earnings per share of 83 cents, surpassing consensus estimate of 78 cents.
2025-09-22 (ET)
2025-09-22
16:20:58
ArriVent Biopharma names Brent Rice as its new chief commercial officer.
2025-09-09 (ET)
2025-09-09
08:08:08
ArriVent Biopharma unveils proof-of-concept findings from Phase 1b FURTHER study
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/d8c78b2bcfb7edee9a1b4a4faa18103b1ea9c247c56bd6656101571b50e5e07e.png)
Preview
4.0
09-10TipRanksTop Analysts Recommend 3 Best Stocks to Purchase Now, 9/10/2025
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/newsfilter.png)
Preview
9.0
09-09NewsfilterArrivent Unveils Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Lung Cancer Conference
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/4f588907c63c6ddb016f398e7ea000ac873412e8a31fa15ad282816643616afb.jpg)
Preview
3.0
08-22NASDAQ.COMExplore the Potential: XBI Could Rise by 55%
Sign Up For More News
People Also Watch
FAQ
What is ArriVent BioPharma Inc (AVBP) stock price today?
What is ArriVent BioPharma Inc (AVBP)'s business?
What is the price predicton of AVBP Stock?
What is ArriVent BioPharma Inc (AVBP)'s revenue for the last quarter?
What is ArriVent BioPharma Inc (AVBP)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for ArriVent BioPharma Inc (AVBP)'s fundamentals?
How many employees does ArriVent BioPharma Inc (AVBP). have?